Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.55 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.55 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.55 |
| ▸ | MMP2 | P08253 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | LTA4H | P09960 | 1/20 | 0.53 |
| ▸ | ANPEP | P15144 | 1/20 | 0.53 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.52 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.52 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | CPB1 | P15086 | 1/20 | 0.50 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.50 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.49 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.49 |
| ▸ | TLR2 | O60603 | 2/20 | 0.49 |
| ▸ | DPP4 | P27487 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19871881 | 1.00 | SIRT2 (0.55) | SIRT2SIRT1SIRT3MMP2MEN1 | |
| SCHEMBL22750107 | 0.92 | SIRT2 (0.62) | SIRT2SIRT1SIRT3MMP2MEN1 | |
| SCHEMBL16217772 | 0.92 | SIRT2 (0.62) | SIRT2SIRT1SIRT3MMP2MEN1 | |
| SCHEMBL29454892 | 0.91 | ANPEP (0.63) | MEN1ALDH1A1HPGDKMT2AANPEP | |
| SCHEMBL12202915 | 0.88 | MEN1 (0.62) | MEN1ALDH1A1HPGDKMT2ALTA4H | |
| SCHEMBL18972974 | 0.88 | SIRT2 (0.70) | SIRT2SIRT1SIRT3MEN1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL16653331 | 0.87 | ANPEP (0.63) | MEN1ALDH1A1HPGDKMT2AANPEP | |
| SCHEMBL24812138 | 0.86 | MEN1 (0.48) | SIRT2SIRT1SIRT3MEN1ALDH1A1 | |
| SCHEMBL18879557 | 0.86 | ANPEP (0.52) | SIRT2SIRT1SIRT3MEN1ALDH1A1 | |
| SCHEMBL29193082 | 0.86 | MEN1 (0.48) | SIRT2SIRT1SIRT3MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552743-B2 | Oligonucleotide compositions and methods of use thereof | WAVE LIFE SCIENCES LTD. (SG) | 2026-02-17 | — | — | US | disclosed |
| US-20230357776-A1 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-11732265-B2 | Compositions and methods for modulating complement factor B expression | IONIS PHARMACEUTICALS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| EP-4219718-A2 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | Ionis Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20230151365-A1 | COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230057718-A1 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2023-02-23 | — | — | US | disclosed |
| US-20220324900-A1 | COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2022-10-13 | — | — | US | disclosed |
| US-20220306573-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2022-09-29 | — | — | US | disclosed |
| US-11312964-B2 | Compositions and methods for modulating growth hormone receptor expression | IONIS PHARMACEUTICALS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-20210395734-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2021-12-23 | — | — | US | disclosed |
| US-9127276-B2 | Conjugated antisense compounds and their use | ISIS PHARMACEUTICALS, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-20150176007-A1 | COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150126718-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2015-05-07 | — | — | US | disclosed |
| WO-2015042447-A1 | TARGETED THERAPEUTIC NUCLEOSIDES AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2015-03-26 | — | — | WO | disclosed |
| US-20140343123-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-20 | — | — | US | disclosed |
| WO-2014179629-A2 | COMPOSITIONS AND METHODS | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014179627-A2 | COMPOSITIONS AND METHODS FOR MODULATING HBV AND TTR EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014179625-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN (a) EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014179626-A2 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014179620-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12552743-B2 | Oligonucleotide compositions and methods of use thereof | NSUN3, NSUN2, SNRPA1 | SIRT2 3490/4885SIRT1 3474/4885SIRT3 2753/4885 |
| US-20220324900-A1 | COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION | TEK, PLIN3, FABP3 | SIRT2 403/4885SIRT1 182/4885SIRT3 204/4885 |
| US-20220306573-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | RBM17, UPF1, RBM22 | SIRT2 2751/4885SIRT1 2219/4885SIRT3 2333/4885 |
| US-20230151365-A1 | COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION | TTR, GALNT1, GALNT3 | SIRT2 2152/4885SIRT1 1370/4885SIRT3 1077/4885 |
| US-20210395734-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION | APOB, APOL1, LDLR | SIRT2 2092/4885SIRT1 1101/4885SIRT3 448/4885 |
| US-20150176007-A1 | COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION | HAVCR2, HCCS, HDGF | SIRT2 2044/4885SIRT1 1268/4885SIRT3 1640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.